- The FDA previously granted ruxolitinib Breakthrough Therapy Designation for the treatment of acute GVHD
- Jakafi is marketed by Incyte in the United States and by Novartis as Jakavi (... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,